1 |
DANNE C, SKERNISKYTE J, MARTEYN B, et al. Neutrophils: from IBD to the gut microbiota[J]. Nat Rev Gastroenterol Hepatol, 2024, 21: 184-197.
|
2 |
BISGAARD T H, ALLIN K H, KEEFER L, et al. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment[J]. Nat Rev Gastroenterol Hepatol, 2022, 19: 717-726.
|
3 |
SCOTT B M, GUTIÉRREZ-VÁZQUEZ C, SANMARCO L M, et al. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease[J]. Nat Med, 2021, 27: 1212-1222.
|
4 |
NEURATH M F. Current and emerging therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14: 269-278.
|
5 |
LE BERRE C, HONAP S, PEYRIN-BIROULET L. Ulcerative colitis [J]. Lancet, 2023, 402(10401): 571-584.
|
6 |
KOBAYASHI T, HIBI T. Improving IBD outcomes in the era of many treatment options[J]. Nat Rev Gastroenterol Hepatol, 2023, 20: 79-80.
|
7 |
MAO R, CHEN M H. Precision medicine in IBD: genes, drugs, bugs and omics[J]. Nat Rev Gastroenterol Hepatol, 2022, 19: 81-82.
|
8 |
COLOMBEL J F, SANDBORN W J, REINISCH W, et al. Infliximab, azathioprine, or combination therapy for Crohn′s disease[J]. N Engl J Med, 2010, 362(15): 1383-1395.
|
9 |
CURVINO E J, ROE E F, FREIRE HADDAD H, et al. Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres[J]. Nat Biomed Eng, 2024, 8: 628-649.
|
10 |
HILL C, GUARNER F, REID G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol, 2014, 11: 506-514.
|
11 |
SALMINEN S, COLLADO M C, ENDO A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics[J]. Nat Rev Gastroenterol Hepatol, 2021, 18: 649-667.
|
12 |
BUTEL M J. Probiotics, gut microbiota and health[J]. Med Mal Infect, 2014, 44(1): 1-8.
|
13 |
LUO H, WU F, WANG X, et al. Encoding bacterial colonization and therapeutic modality by wrapping with an adhesive drug-loadable nanocoating[J]. Mater Today, 2023, 62: 98-110.
|
14 |
SONG W F, YAO W Q, CHEN Q W, et al. In situ bioorthogonal conjugation of delivered bacteria with gut inhabitants for enhancing probiotics colonization[J]. ACS Cent Sci, 2022, 8(9): 1306-1317.
|
15 |
KURTZ C B, MILLET Y A, PUURUNEN M K, et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans[J]. Sci Transl Med, 2019, 11(475): eaau7975.
|
16 |
WANG X, CAO Z, ZHANG M, et al. Bioinspired oral delivery of gut microbiota by self-coating with biofilms[J]. Sci Adv, 2020, 6(26): eabb1952.
|
17 |
CARONE M, SPALINGER M R, GAULTNEY R A, et al. Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis[J]. Nat Commun, 2023, 14: 3489.
|
18 |
YASMIN F, NAJEEB H, SHAIKH S, et al. Novel drug delivery systems for inflammatory bowel disease[J]. World J Gastroenterol, 2022, 28(18): 1922-1933.
|
19 |
LIU H, CAI Z, WANG F, et al. Colon-targeted adhesive hydrogel microsphere for regulation of gut immunity and flora[J]. Adv Sci, 2021, 8(18): e2101619.
|
20 |
HUANG H B, GONG W, HOU Y Y, et al. Mucoadhesive hydrogel with anti-gastric acid and sustained-release functions for amelioration of DSS-induced ulcerative colitis[J]. J Agric Food Chem, 2023, 71(9): 4016-4028.
|
21 |
ZHANG K, ZHU L, ZHONG Y, et al. Prodrug integrated envelope on probiotics to enhance target therapy for ulcerative colitis[J]. Adv Sci (Weinh), 2023, 10(4): e2205422.
|
22 |
ZHANG S, ERMANN J, SUCCI M D, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease[J]. Sci Transl Med, 2015, 7(300): 300ra128.
|
23 |
MING Z, HAN L, BAO M, et al. Living bacterial hydrogels for accelerated infected wound healing[J]. Adv Sci (Weinh), 2021, 8(24): e2102545.
|